# Clinical trials recruiting in Oklahoma: 832 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 832 trials recruiting or not yet recruiting with a site in Oklahoma, as read on November 19, 2026.

## The full list

Clinical trials recruiting in Oklahoma: 832 rows for $41.60, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 15 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/state/oklahoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 832
- Recruiting or not yet: 832
- Read on: November 19, 2026

## Trials

The 25 newest of 832, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 10, 2026 | NCT07929506 | Prophylactic CPAP for Late Preterm Infants Born by C-Section to Reduce NICU Admission | Indiana University | Not applicable | Not yet recruiting | Late Preterm Infant | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07929506) |
| November 5, 2026 | NCT07920484 | A Clinical Study to Collect Real-wordt Data on Safety and Clinical Performance of the VCFix Spinal System for Treatment of Vertebral... | Amber Implants B.V. | Observational | Recruiting | Vertebra Compression Fracture | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07920484) |
| November 5, 2026 | NCT07919678 | A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1) | Pfizer | Phase 3 | Recruiting | Obesity, Overweight, Osteoarthritis of the Knee | 656 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919678) |
| November 5, 2026 | NCT07919405 | A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Hypertension, Obesity | 1,408 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919405) |
| November 4, 2026 | NCT07915791 | A Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Adult Participants With Moderate to Severe... | GlaxoSmithKline | Phase 2 | Recruiting | Pulmonary Disease, Chronic Obstructive | 279 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915791) |
| October 16, 2026 | NCT07878923 | Early Versus Delayed Start of Ocrevus Zunovo for Relapsing Multiple Sclerosis | Oklahoma Medical Research Foundation | Observational | Recruiting | Relapse Remitting Multiple Sclerosis | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07878923) |
| October 15, 2026 | NCT07875569 | Remote vs. In-Person Study Evaluation (RISE) Trials: RISE Above Opioid Overdose (Trial 3 of 3) | State University of New York at Buffalo | Not applicable | Not yet recruiting | Remote vs. In-Person, Remote Visits, In-person Visits | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07875569) |
| October 13, 2026 | NCT07871409 | Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight | Amgen | Phase 3 | Recruiting | Obesity, Overweight | 230 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07871409) |
| October 9, 2026 | NCT07869043 | A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe Asthma | Pfizer | Phase 3 | Recruiting | Asthma | 1,100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07869043) |
| October 9, 2026 | NCT07867080 | A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME). | 4D Molecular Therapeutics | Phase 3 | Recruiting | Diabetic Macular Edema (DME) | 514 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07867080) |
| October 8, 2026 | NCT07866131 | Observational Assessment of Skin Appearance Changes During PRX S Cosmetic Treatment in Participants With Acne-Prone Skin | WiQo S.p.A. | Not applicable | Recruiting | Acne-prone Skin, Skin Disease | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07866131) |
| October 6, 2026 | NCT07861100 | A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Cardiovascular Risk, Obesity | 8,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07861100) |
| October 5, 2026 | NCT07857616 | SI-B036-ST-101 in Advanced/Metastatic Solid Tumors | SystImmune Inc. | Phase 1 | Recruiting | Locally Advanced /Metastatic Solid Tumors, Locally Advanced / Metastatic Solid Tumors, Metastatic Solid Cancers, Non... | 424 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07857616) |
| September 29, 2026 | NCT07845474 | A Manualized Recreational Therapy Balance Program for Older Adults With Parkinson's and Movement Disorders | Oklahoma State University | Not applicable | Not yet recruiting | Parkinson Disease (PD), Postural Balance, Movement Disorders (Incl Parkinsonism), Postural Balance, Accidental Falls | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07845474) |
| September 28, 2026 | NCT07845071 | An Open-Label, Safety and Efficacy Study of Cebranopadol in Participants With Acute Pain With Surgical or Non-Surgical Origin | Adneuris Therapeutics, Inc. | Phase 3 | Recruiting | Pain | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07845071) |
| September 28, 2026 | NCT07843654 | Parenting-STAIR Modular for Military Fathers and OCONUS Families | New York University | Not applicable | Not yet recruiting | Depressive Symptoms, Emotional Depression, Depression, Parent Child Relationship, Parent-Child Relationship... | 243 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07843654) |
| September 25, 2026 | NCT07840326 | A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS) | Sundance Biosciences, Inc. | Phase 2 | Recruiting | Primary Progressive Multiple Sclerosis, Primary Progressive MS, Primary Progressive Multiple Sclerosis (PPMS)... | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07840326) |
| September 24, 2026 | NCT07837973 | Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss | Alveus Therapeutics, Inc. | Phase 2 | Recruiting | Overweight , Obesity, Adults | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07837973) |
| September 22, 2026 | NCT07833566 | Biopsy-site-marker in Breast Cancer | University of Oklahoma | Observational | Recruiting | Breast Cancer | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07833566) |
| September 22, 2026 | NCT07832617 | Protoacoustic Imaging For 3D Mapping | University of Oklahoma | Observational | Recruiting | Proton Therapy, Radiation Therapy, Secondary Skin Reactions, Liver Cancer, Prostate Cancer | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07832617) |
| September 21, 2026 | NCT07830732 | A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A | Novo Nordisk A/S | Phase 3 | Recruiting | Haemophilia A | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07830732) |
| September 18, 2026 | NCT07829185 | Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer | University of Oklahoma | Phase 1 | Recruiting | Pancreatic Ductal Adenocarcinoma (PDAC) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07829185) |
| September 17, 2026 | NCT07825857 | Randomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorder | University of Texas Southwestern Medical Center | Phase 2 | Recruiting | Methamphetamine Use Disorder | 228 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07825857) |
| September 14, 2026 | NCT07817875 | Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12... | Eli Lilly and Company | Phase 3 | Recruiting | Obesity | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07817875) |
| September 14, 2026 | NCT07816666 | Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer | AstraZeneca | Phase 3 | Recruiting | Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer... | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07816666) |

## Sites with the most of these trials

Sites as the records name them, organizations only.

| Site | City | Trials |
| --- | --- | --- |
| University of Oklahoma Health Sciences Center | Oklahoma City | 192 |
| Mercy Hospital Oklahoma City | Oklahoma City | 51 |
| University of Oklahoma | Oklahoma City | 31 |
| Cancer Centers of Southwest Oklahoma Research | Lawton | 24 |
| OU Health Stephenson Cancer Center | Oklahoma City | 24 |
| Stephenson Cancer Center | Oklahoma City | 15 |
| Oklahoma Cancer Specialists and Research Institute-Tulsa | Tulsa | 15 |
| Oklahoma Medical Research Foundation | Oklahoma City | 14 |
| Hightower Clinical | Oklahoma City | 12 |
| Oklahoma Heart Institute | Tulsa | 11 |
| Saint Francis Children's Hospital | Tulsa | 11 |
| The University of Oklahoma Health Sciences Center | Oklahoma City | 11 |
| University of Oklahoma Health Campus | Oklahoma City | 10 |
| Laureate Institute for Brain Research | Tulsa | 10 |
| Oklahoma Cancer Specialists and Research Institute, LLC | Tulsa | 9 |
| Oklahoma Heart Hospital | Oklahoma City | 8 |
| Saint Francis Hospital | Tulsa | 8 |
| Lynn Health Science Institute | Oklahoma City | 7 |
| Lynn Institute of Norman | Norman | 7 |
| The Movement Disorder Clinic of Oklahoma | Tulsa | 6 |
| Integris Southwest Medical Center | Oklahoma City | 6 |
| TSET Health Promotion Research Center | Oklahoma City | 6 |
| Central States Research | Tulsa | 5 |
| Sooner Clinical Research | Oklahoma City | 5 |
| University of Oklahoma Health Science Center | Oklahoma City | 5 |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 9 |
| Phase 1 | 50 |
| Phase 1/2 | 42 |
| Phase 2 | 171 |
| Phase 2/3 | 27 |
| Phase 3 | 283 |
| Phase 4 | 24 |
| Not applicable | 142 |
| Observational | 84 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Non-Small-Cell Lung | 37 |
| Endometrial Neoplasms | 32 |
| Ovarian Neoplasms | 30 |
| Colorectal Neoplasms | 28 |
| Obesity | 25 |
| Breast Neoplasms | 25 |
| Prostatic Neoplasms | 25 |
| Lung Neoplasms | 22 |
| Heart Failure | 22 |
| Neoplasms | 20 |
| Overweight | 19 |
| Neoplasm Metastasis | 19 |
| Squamous Cell Carcinoma of Head and Neck | 16 |
| Cardiovascular Diseases | 15 |
| Melanoma | 15 |
| Leukemia, Myeloid, Acute | 15 |
| Diabetes Mellitus, Type 2 | 14 |
| Depressive Disorder, Major | 14 |
| Fallopian Tube Neoplasms | 14 |
| Pancreatic Neoplasms | 13 |
| Asthma | 13 |
| Stomach Neoplasms | 13 |
| Urinary Bladder Neoplasms | 13 |
| Triple Negative Breast Neoplasms | 12 |
| Uterine Cervical Neoplasms | 12 |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| University of Oklahoma | 79 |
| National Cancer Institute (NCI) | 73 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 26 |
| Alliance for Clinical Trials in Oncology | 22 |
| SWOG Cancer Research Network | 21 |
| Children's Oncology Group | 19 |
| NRG Oncology | 18 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 18 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 15 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 11 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 10 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 10 |
| Laureate Institute for Brain Research, Inc. | 10 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 10 |
| [Amgen](https://specstream.ai/data/clinical-trials/company/amgen) | 9 |
| [Janssen Research & Development, LLC](https://specstream.ai/data/clinical-trials/company/janssen-research-and-development-llc) | 9 |
| [Novo Nordisk A/S](https://specstream.ai/data/clinical-trials/company/novo-nordisk-a-s) | 8 |
| ECOG-ACRIN Cancer Research Group | 8 |
| [Hoffmann-La Roche](https://specstream.ai/data/clinical-trials/company/hoffmann-la-roche) | 6 |
| [Sanofi](https://specstream.ai/data/clinical-trials/company/sanofi) | 6 |
| [Boehringer Ingelheim](https://specstream.ai/data/clinical-trials/company/boehringer-ingelheim) | 5 |
| [Intra-Cellular Therapies, Inc.](https://specstream.ai/data/clinical-trials/company/intra-cellular-therapies-inc) | 5 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 5 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 5 |
| [Edwards Lifesciences](https://specstream.ai/data/clinical-trials/company/edwards-lifesciences) | 5 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in Oklahoma

- [Oral and maxillofacial surgery practices in Oklahoma, United States](https://specstream.ai/data/businesses/oral-and-maxillofacial-surgery-practices/oklahoma-united-states)
- [Flooring contractors in Oklahoma, United States](https://specstream.ai/data/businesses/flooring-contractors/oklahoma-united-states)
- [Bankruptcy law firms in Oklahoma, United States](https://specstream.ai/data/businesses/bankruptcy-law-firms/oklahoma-united-states)
- [Rehabilitation centers in Oklahoma, United States](https://specstream.ai/data/businesses/rehabilitation-centers/oklahoma-united-states)
- [Laboratories in Oklahoma, United States](https://specstream.ai/data/businesses/laboratories/oklahoma-united-states)
- [Countertop installers in Oklahoma, United States](https://specstream.ai/data/businesses/countertop-installers/oklahoma-united-states)
